EA200870304A1 - Псевдоинфекционный флавивирус и его применение - Google Patents

Псевдоинфекционный флавивирус и его применение

Info

Publication number
EA200870304A1
EA200870304A1 EA200870304A EA200870304A EA200870304A1 EA 200870304 A1 EA200870304 A1 EA 200870304A1 EA 200870304 A EA200870304 A EA 200870304A EA 200870304 A EA200870304 A EA 200870304A EA 200870304 A1 EA200870304 A1 EA 200870304A1
Authority
EA
Eurasian Patent Office
Prior art keywords
flavivirus
capsid
viruses
pseudo
pseudoinfectional
Prior art date
Application number
EA200870304A
Other languages
English (en)
Other versions
EA016490B1 (ru
Inventor
Илья Фролов
Елена Фролова
Питер С. Мэйсон
Original Assignee
Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем filed Critical Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем
Publication of EA200870304A1 publication Critical patent/EA200870304A1/ru
Publication of EA016490B1 publication Critical patent/EA016490B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем изобретении описывается дефектный по репликации псевдоинфекционный вирус семейства Flaviviridae, не содержащий гена капсида, где дефектный по репликации псевдоинфекционный вирус размножается только в клетках, экспрессирующих капсид или капсид, prM и белок оболочки флавивируса. В настоящем изобретении также описывается способ широкомасштабного производства таких вирусов и использование таких псевдоинфекционных вирусов в качестве вакцин для профилактики заболеваний, вызванных инфекциями человека и животных вирусами, принадлежащими к этому семейству.
EA200870304A 2006-02-27 2007-02-27 Псевдоинфекционный флавивирус и его применение EA016490B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77718906P 2006-02-27 2006-02-27
PCT/US2007/004957 WO2007098267A2 (en) 2006-02-27 2007-02-27 Pseudoinfectious flavivirus and uses thereof

Publications (2)

Publication Number Publication Date
EA200870304A1 true EA200870304A1 (ru) 2009-02-27
EA016490B1 EA016490B1 (ru) 2012-05-30

Family

ID=38438014

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870304A EA016490B1 (ru) 2006-02-27 2007-02-27 Псевдоинфекционный флавивирус и его применение

Country Status (20)

Country Link
US (2) US8252574B2 (ru)
EP (1) EP1991709B1 (ru)
JP (2) JP5538729B2 (ru)
KR (1) KR101499750B1 (ru)
CN (1) CN101454022B (ru)
AP (1) AP2008004629A0 (ru)
AU (1) AU2007217352B2 (ru)
BR (1) BRPI0708332A2 (ru)
CA (1) CA2643819C (ru)
CO (1) CO6141481A2 (ru)
CR (1) CR10323A (ru)
EA (1) EA016490B1 (ru)
HN (1) HN2008001324A (ru)
IL (1) IL193522A (ru)
MY (1) MY151062A (ru)
NZ (1) NZ570881A (ru)
SG (1) SG172642A1 (ru)
UA (1) UA101597C2 (ru)
WO (1) WO2007098267A2 (ru)
ZA (1) ZA200807544B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017206A2 (en) * 2004-07-12 2006-02-16 Tengen Biomedical Company Flavivirus vaccine
SG172642A1 (en) 2006-02-27 2011-07-28 Univ Texas Pseudoinfectious flavivirus and uses thereof
JP5779352B2 (ja) 2008-03-14 2015-09-16 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 複製欠損フラビウイルスワクチンおよびワクチンベクター
US20120128713A1 (en) * 2009-03-16 2012-05-24 Sanofi Pasteur Limited Replication-Defective Flavivirus Vaccine Vectors Against Respiratory Syncytial Virus
US8568739B2 (en) 2009-05-28 2013-10-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses
BRPI0914507A2 (pt) * 2009-12-23 2012-04-10 Fundacao Oswaldo Cruz vacina para lentivìrus baseada em vìrus recombinante vacinal da febre amarela
WO2012027473A2 (en) * 2010-08-24 2012-03-01 The University Of North Carolina At Chapel Hill Immunogenic compositions comprising alphavirus vectored dengue virus e protein antigens
US9402890B2 (en) * 2011-02-01 2016-08-02 Uab Research Foundation Methods and compositions for pseudoinfectious alphaviruses
AU2013208187B2 (en) * 2012-01-09 2018-07-12 Sanofi Pasteur Biologics, Llc Purification of flaviviruses
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
US8961995B2 (en) * 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
HUE043096T2 (hu) * 2014-06-20 2019-07-29 Univ Aix Marseille Eljárás egy fertõzõ RNS vírus gyors létrehozására
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
WO2018048869A1 (en) * 2016-09-06 2018-03-15 Bioventures, Llc Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors
US10590171B2 (en) 2016-10-28 2020-03-17 The Board Of Regents Of The University Of Texas System Exosomes and methods of making and using the same
CA3053289A1 (en) * 2017-02-14 2018-08-23 Xuping XIE Live attenuated zika virus with 3'utr deletion, vaccine containing and use thereof
BR112019023477A2 (pt) 2017-05-08 2020-06-30 Gritstone Oncology, Inc. vetores de neoantígeno de alfavírus
KR20200118029A (ko) 2018-01-04 2020-10-14 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
WO2021138447A1 (en) 2019-12-31 2021-07-08 Elixirgen Therapeutics, Inc. Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
US11759515B2 (en) * 2020-03-09 2023-09-19 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
KR20230046313A (ko) 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 다중에피토프 백신 카세트
WO2022249757A1 (ja) * 2021-05-27 2022-12-01 マイキャン・テクノロジーズ株式会社 疑似ウイルスを使用した抗体依存性感染増強反応の評価法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028487A1 (en) 1997-11-28 1999-06-10 The Crown In The Right Of The Queensland Department Of Health Flavivirus expression and delivery system
DE69942525D1 (de) 1998-09-02 2010-08-05 Us Government Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff
EP1165842A4 (en) 1999-03-16 2004-07-07 Dana Farber Cancer Inst Inc LENTIVIRAL VECTOR SYSTEMS FOR SCREENING LARGE QUANTITIES
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
WO2002072803A2 (en) 2001-03-09 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Subgenomic replicons of the flavivirus dengue
JP2005510244A (ja) * 2001-11-26 2005-04-21 ザ・ユニヴァーシティ・オヴ・クイーンズランド フラビウイルスワクチン送達系
US7244434B2 (en) * 2002-08-13 2007-07-17 Intervet International B.V. Replicons of pestviruses that do not express C and or E1 protein and infectious viral particles containing same, that can be used in vaccines
WO2004022761A1 (en) 2002-09-03 2004-03-18 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
JP5250179B2 (ja) * 2002-11-08 2013-07-31 ザ アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド フラビウイルス融合インヒビター
US6943015B2 (en) 2002-12-12 2005-09-13 Ilya Frolov Large scale production of packaged alphavirus replicons
EP1593738A4 (en) 2003-01-30 2006-05-31 Shanghai Tengen Biomedical Co VIRUSELY PARTICULATE VACCINE WITH RECOMBINANT DENGUEVIRUS REPLICANT AS ITS SUPPORT
MXPA05010429A (es) * 2003-03-31 2005-11-04 Hoffmann La Roche Composiciones y metodos para detectar ciertos flavivirus que incluyen miembros del serogrupo del virus de la encefalitis japonesa.
AU2003902842A0 (en) 2003-06-06 2003-06-26 The University Of Queensland Flavivirus replicon packaging system
WO2006017206A2 (en) 2004-07-12 2006-02-16 Tengen Biomedical Company Flavivirus vaccine
SG172642A1 (en) 2006-02-27 2011-07-28 Univ Texas Pseudoinfectious flavivirus and uses thereof

Also Published As

Publication number Publication date
CN101454022B (zh) 2013-09-04
US20090155301A1 (en) 2009-06-18
NZ570881A (en) 2011-09-30
EA016490B1 (ru) 2012-05-30
AP2008004629A0 (en) 2008-10-31
SG172642A1 (en) 2011-07-28
AU2007217352B2 (en) 2013-09-26
CA2643819C (en) 2018-11-27
BRPI0708332A2 (pt) 2011-05-24
KR20090008193A (ko) 2009-01-21
KR101499750B1 (ko) 2015-03-06
JP2014121324A (ja) 2014-07-03
JP5538729B2 (ja) 2014-07-02
CA2643819A1 (en) 2007-08-30
CN101454022A (zh) 2009-06-10
ZA200807544B (en) 2009-11-25
EP1991709B1 (en) 2017-01-25
HN2008001324A (es) 2010-10-29
UA101597C2 (ru) 2013-04-25
IL193522A0 (en) 2009-05-04
JP2009528032A (ja) 2009-08-06
CR10323A (es) 2009-01-29
CO6141481A2 (es) 2010-03-19
US8252574B2 (en) 2012-08-28
WO2007098267A3 (en) 2008-11-20
MY151062A (en) 2014-03-31
WO2007098267A2 (en) 2007-08-30
EP1991709A2 (en) 2008-11-19
EP1991709A4 (en) 2009-10-21
US9273288B2 (en) 2016-03-01
AU2007217352A1 (en) 2007-08-30
US20130023031A1 (en) 2013-01-24
IL193522A (en) 2014-05-28

Similar Documents

Publication Publication Date Title
EA200870304A1 (ru) Псевдоинфекционный флавивирус и его применение
EA201490654A1 (ru) Новые ингибиторы вирусной репликации
BRPI0913012A2 (pt) vírus do nilo ocidental/da dengue quiméricos
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
CL2011002453A1 (es) Compuestos derivados de diazol u oxazol-pirrol o pirrolciclopropil condensados sustituidos, inhibidores de la función de la proteína ns5a codificada por el virus de la hepatitis c (vhc); composición farmacéutica; y su uso para el tratamiento de una infección por vhc.
PH12015502230A1 (en) Novel viral replication inhibitors
CY1112848T1 (el) Αναστολεις του ιου της ηπατιτιδας c
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
MX2009011064A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
NO20090453L (no) Hepatitt C Virusinhibitorer
ATE494906T1 (de) Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
ECSP066626A (es) Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
WO2009039248A8 (en) Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
MX2010009563A (es) Compuestos quimicos con accion antiviral contra virus de dengue y otros flavivirus.
EA200701850A1 (ru) Соединения трициклических нуклеозидов (варианты), фармацевтическая композиция на их основе и способ лечения или профилактики вирусных инфекций у млекопитающих
EA200900298A1 (ru) Ингибиторы вируса гепатита с
WO2010107739A3 (en) Methods and compositions of treating a flaviviridae family viral infection
EA201000277A1 (ru) Соединения для лечения гепатита с
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
ME01140B (me) Virus goveđe virusne dijareje s modifikovanim erns proteinom
WO2013106689A8 (en) Hcv ns3 protease inhibitors
AR057641A1 (es) Compuestos 5- nitro - nucleosidos para tratar infecciones virales
WO2012061248A8 (en) Novel specific hcv ns3 protease inhibitors
WO2010107742A3 (en) Methods and compositions of treating a flaviviridae family viral infection

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU